Key facts
- This page summarizes Barbara Galaini's Form 4 filing for TYME TECHNOLOGIES, INC..
- 7 reported transactions and 6 derivative rows are listed below.
- Accepted by SEC: 16 Sep 2022, 18:00.
Barbara Galaini - 16 Sep 2022 Form 4 Insider Report for TYME TECHNOLOGIES, INC.
- Reporting relationship
- Principal Accounting Officer and Controller
- Issuer ticker
- N/A
- Reported as of
- 16 Sep 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 16 Sep 2022, 18:00:41 UTC
- Prior SEC filing
- 26 Apr 2022
- Source filing
- View source filing
- Reporting owner signature
- By: /s/ Richard Cunningham as attorney-in-fact for Barbara Galaini
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Barbara Galaini filed Form 4 for TYME TECHNOLOGIES, INC. on 16 Sep 2022.
Change
- Previous filing in this sequence was filed on 26 Apr 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TYME
transaction
Common Stock
Disposed to Issuer
- Transaction value
- Shares
- -258,300
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 16 Sep 2022
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TYME
transaction
Derivative
Employee Stock Option - Option to buy
Disposed to Issuer
- Transaction value
- Shares
- -200,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 16 Sep 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 200,000
- Exercise price
- $2.25
- Footnotes
- F2
TYME
transaction
Derivative
Employee Stock Option - Option to buy
Disposed to Issuer
- Transaction value
- Shares
- -50,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 16 Sep 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 50,000
- Exercise price
- $2.25
- Footnotes
- F3
TYME
transaction
Derivative
Employee Stock Option - Option to buy
Disposed to Issuer
- Transaction value
- Shares
- -179,700
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 16 Sep 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 179,700
- Exercise price
- $1.56
- Footnotes
- F4
TYME
transaction
Derivative
Employee Stock Option - Option to buy
Disposed to Issuer
- Transaction value
- Shares
- -225,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 16 Sep 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 225,000
- Exercise price
- $1.39
- Footnotes
- F5
TYME
transaction
Derivative
Employee Stock Option - Option to buy
Disposed to Issuer
- Transaction value
- Shares
- -280,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 16 Sep 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 280,000
- Exercise price
- $1.43
- Footnotes
- F6
TYME
transaction
Derivative
Employee Stock Option - Option to buy
Disposed to Issuer
- Transaction value
- Shares
- -258,300
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 16 Sep 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 258,300
- Exercise price
- $0.3200
- Footnotes
- F7
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Barbara Galaini is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 7 footnotes
Footnote F1
Disposed of pursuant to the merger agreement between the issuer and Syros Pharmaceuticals, Inc. ("Syros") in exchange for 11,318 shares of Syros common stock having a market value of $7.30 per share at the close of trading on September 15, 2022, the last trading day immediately preceding the effective time of the merger, but after giving effect to a 1-for-10 reverse stock split by Syros (the "Reverse Split"), with cash paid in lieu of fractional shares.
Footnote F2
This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 8,764 shares of Syros common stock for $51.35 per share, after giving effect to the Reverse Split.
Footnote F3
This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 2,191 shares of Syros common stock for $51.35 per share, after giving effect to the Reverse Split.
Footnote F4
This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 7,874 shares of Syros common stock for $35.60 per share, after giving effect to the Reverse Split.
Footnote F5
This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 9,859 shares of Syros common stock for $31.72 per share, after giving effect to the Reverse Split.
Footnote F6
This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 12,269 shares of Syros common stock for $32.63 per share, after giving effect to the Reverse Split.
Footnote F7
This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 11,318 shares of Syros common stock for $7.30 per share, after giving effect to the Reverse Split.
SEC remarks
Principal Accounting Officer and Controller